Print page

New Nutraceutical Addresses An Unfilled Gap In Postmenopausal Bone Health

Metagenics Inc. has launched a new nutraceutical called Ostera. The nutritional supplement supports the special needs of postmenopausal women, whose bone health may be affected by declining estrogen levels.*

Ostera is formulated to target bone remodeling, the normal lifelong process whereby old or damaged bone tissue is replaced by new bone tissue. The new nutraceutical is a gentle, all-natural formula without reported serious adverse effects.

Ostera is intended to complement natural bone mineralization support products, such as calcium and other minerals.* According to Metagenics, Ostera's active ingredients include:

• Extracts from berberine and rho iso-alpha acids from hops — key botanical compounds shown to beneficially influence key markers of bone remodeling. In postmenopausal women, a decline in estrogen levels can contribute to changes in bone remodeling, where the rate of bone breakdown outpaces the rate of new bone formation.*
• Vitamin K – necessary for the metabolism of bone proteins crucial to bone integrity.*
• Vitamin D – associated with healthy bone formation and bone mineralization.*

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Company Information

Website: www.metagenics.com